Authors:
RUEDA F
MARTI F
PARDO N
BADELL I
PEIRO M
BERTRAN E
VILLEN E
GARCIA J
CUBELLS J
Citation: F. Rueda et al., INTERLEUKIN-2 IN NEUROBLASTOMA - CLINICAL PERSPECTIVES BASED ON BIOLOGICAL STUDIES, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(5), 1996, pp. 303-308
Authors:
PARDO N
MARTI F
FRAGA G
ILLA J
BADELL I
PEIRO M
BERTRAN E
GARCIA J
RUEDA F
CUBELLS J
Citation: N. Pardo et al., HIGH-DOSE SYSTEMIC INTERLEUKIN-2 THERAPY IN STAGE-IV NEUROBLASTOMA FOR ONE-YEAR AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION - PILOT-STUDY, Medical and pediatric oncology, 27(6), 1996, pp. 534-539
Authors:
MARTI F
MUNOZ J
PEIRO M
BERTRAN E
FERRAN C
OCTAVIO C
GARCIA J
RUEDA F
Citation: F. Marti et al., HIGHER CYTOTOXIC ACTIVITY AND INCREASED LEVELS OF IL-1-BETA, IL-6, AND TNF-ALPHA IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS, American journal of hematology, 49(3), 1995, pp. 237-239
Authors:
MARTI F
PARDO N
PEIRO M
BERTRAN E
AMILL B
GARCIA J
CUBELLS J
RUEDA F
Citation: F. Marti et al., PROGRESSION OF NATURAL IMMUNITY DURING ONE-YEAR TREATMENT OF RESIDUALDISEASE IN NEUROBLASTOMA PATIENTS WITH HIGH-DOSES OF INTERLEUKIN-2 AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION, Experimental hematology, 23(14), 1995, pp. 1445-1452
Authors:
MARTI F
PETRIZ J
PEIRO M
AMILL B
BERTRAN E
TUGUES D
SANCHEZ T
RUEDA F
GARCIA J
Citation: F. Marti et al., FUNCTIONAL AND PHENOTYPE COMPARATIVE-STUDY BETWEEN NATURAL-KILLER ANDINTERLEUKIN-2-ACTIVATED KILLER CYTOTOXICITIES FROM ELUTRIATION SAMPLES, Experimental hematology, 21(8), 1993, pp. 1119-1119
Authors:
MARTI F
MIRALLES A
PEIRO M
AMILL B
DEDALMASES C
PINOL G
RUEDA F
GARCIA J
Citation: F. Marti et al., DIFFERENTIAL EFFECT OF CRYOPRESERVATION ON NATURAL-KILLER-CELL AND LYMPHOKINE-ACTIVATED KILLER-CELL ACTIVITIES, Transfusion, 33(8), 1993, pp. 651-655